A cutting-edge radiation therapy approach using alpha particles is emerging as a potentially transformative treatment for prostate and bladder cancers. While alpha particles are highly effective at killing tumor cells, their therapeutic use has historically been limited due to their extremely short range in human tissue.
A novel technique called Alpha DaRT seeks to overcome this limitation by delivering alpha-emitting atoms directly into solid tumors, potentially opening new avenues for precision radiation therapy beyond conventional beta or gamma radiation.
Alpha DaRT is currently under investigation for a wide array of cancers, including lung, pancreatic, and skin cancers. In the genitourinary oncology space, it shows particular promise for prostate and bladder cancers, where precision treatment is crucial to protect surrounding organs while effectively targeting tumor tissue.
A feasibility study (NCT04543903) is underway to evaluate Alpha DaRT as a neoadjuvant therapy in prostate cancer. The trial plans to enroll 10 adult patients with confirmed prostate adenocarcinoma, with primary endpoints focused on safety and feasibility. The study’s primary completion is anticipated in December 2026.
Inside the Technology
Robert B. Den, MD, Chief Medical Officer at Alpha Tau Medical and associate professor of radiation oncology, cancer biology, and urology at Thomas Jefferson University, explained Alpha DaRT in a recent interview.
“Alpha DaRT uses small stainless steel or titanium seeds coated with radium-224, a radioactive element. These seeds act as scaffolds, releasing alpha particles locally within the tumor. The treatment allows a potent alpha dose to penetrate approximately 5 mm from the seed, providing highly targeted tumor destruction while sparing surrounding tissue,” said Dr. Den.
In genitourinary cancers, the technology offers a unique advantage. Preclinical studies demonstrate that Alpha DaRT can precisely target tumors in the prostate and bladder while minimizing damage to critical structures like the rectum and urethra. Additionally, the therapy appears capable of stimulating a robust immune response, potentially enhancing the effectiveness of immunotherapy, even in patients who have previously shown resistance.
Clinical Applications and Future Directions
The ongoing pilot study focuses on patients with recurrent prostate cancer who have previously undergone radiation, a population for whom additional interventions are challenging. Researchers aim to ensure safe delivery of Alpha DaRT while optimizing its intratumoral application using a novel treatment grid and planning software. Secondary endpoints will assess efficacy, including prostate-specific antigen control.
Looking ahead, Dr. Den envisions Alpha DaRT as a versatile addition to the cancer treatment landscape. “This technology could complement current therapies, offer an alternative in high-risk cases, and expand treatment options for patients with limited alternatives. Its compatibility with immunotherapy could further broaden its clinical impact, potentially even in metastatic disease,” he noted.
Alpha DaRT is also being evaluated for non-genitourinary cancers, such as glioblastoma, pancreatic cancer, and skin cancer, across multiple medical specialties. The therapy’s ability to deliver potent alpha radiation directly to tumors represents a promising advancement in precision oncology.
Dr. Den emphasized, “Alpha DaRT allows access to a highly potent form of radiation that was previously limited to systemic therapy. Our goal is to replicate the survival benefits of alpha radiation in a localized, intratumoral setting, offering new hope for patients with prostate and bladder cancers.”
READ MORE
Post Malone Reveals 60-Pound Weight Loss and Shares Health Strategies
Signs of men Taking Too Much Creatine — But Overdoses Are Rare
Average Waist Size in UK Men Revealed: Why It Matters More Than BMI
